Dyadic Reports Q3 2025 Financial Results and Achieves Key Commercial Milestones

Dyadic International has announced its Q3 2025 financial results and highlighted strategic progress, including a strategic pivot to commercial focus, rebranding as Dyadic Applied BioSolutions, and launching a redesigned website. The company has advanced multiple recombinant protein programs, achieved key development and commercial milestones across life sciences and nutrition markets, received its first purchase order in cell culture media and molecular biology reagent segments, and secured an ERS Genomics CRISPR license. Dyadic's cash position has strengthened through an equity offering, with $10.4 million as of September 30, 2025.